04/03/2024
💥Semaglutide is a glucagon-like peptide (GLP-1) analog. GLP-1 is a hormone produced in the small intestine that stimulates insulin secretion and inhibits glucagon secretion thereby lowering blood sugar.
​
💥 Studies show that semaglutide reduces appetite, improves control of eating, and reduces food cravings in addition to improving glycemic control.
💥Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin secretion that are also expressed in regions of the brain that regulate food intake. Five clinical trials in type 2-diabetic subjects (SURPASS 1–5) have shown that tirzepatide at 5–15 mg per week reduces both HbA1c (1.24 to 2.58%) and body weight (5.4–11.7 kg) by amounts unprecedented for a single agent.
